News
BCTX
2.190
-5.60%
-0.130
BriaCell Showcases Cancer Immunotherapy Advances at ASCO
TipRanks · 12h ago
BriaCell Announces Oral and Poster Presentations at ASCO 2024
BriaCell Therapeutics Corp. Is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. An oral presentation on the clinical data of the Bria-IMT study will be presented at the 2024 American Society of Clinical Oncology Annual Meeting.
Barchart · 18h ago
Weekly Report: what happened at BCTX last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at BCTX last week (0408-0412)?
Weekly Report · 04/15 11:11
BriaCell’s Novel Cancer Treatments Show Promise
TipRanks · 04/10 12:37
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity Of Bria-OTS+ And Bria-PROS+ Clinical Candidates For Breast And Prostate Cancer
BriaCell Therapeutics Corp. Reports preclinical data showing strong anti-cancer activity of its next generation breast and prostate cancer immunotherapies. BriaCell's Bria-OTS+™ and bria-PROS+™ induce an anti- cancer immune response via multiple mechanisms including naïve helper and killer T cells and natural killer cells. The novel mechanisms of action may lead to strong activity in cancer patients. The company expects to use bria cell's immunotherapy in its upcoming phase 1/2a clinical studies for cancer.
Benzinga · 04/10 12:10
BriaCell Highlights Data For Antibody-Drug Conjugate Resistant And Central Nervous System Metastatic Breast Cancer At AACR 2024
PFS of 4.2 months in ADC resistant patients receiving Bria-IMT™ is twice that of controls in similar studies. The drug has a clinical benefit rate of 56% in evaluable patients. The study shows potential to manage CNS metastatic disease in advanced breast cancer.
Benzinga · 04/09 12:49
BriaCell’s Bria-IMT™ Shows Groundbreaking Treatment Efficacy
TipRanks · 04/09 12:38
Weekly Report: what happened at BCTX last week (0401-0405)?
Weekly Report · 04/08 11:17
BriaCell Subsidiary Releases Unaudited Mid-Year Financials
TipRanks · 04/02 20:25
Weekly Report: what happened at BCTX last week (0325-0329)?
Weekly Report · 04/01 11:14
Weekly Report: what happened at BCTX last week (0318-0322)?
Weekly Report · 03/25 11:17
BCTX Stock Earnings: BriaCell Therapeutics Reported Results for Q2 2024
BriaCell Therapeutics reported earnings per share of -71 cents for the second quarter of 2024. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports. BriaCell reported results for second quarter 2024.
Investorplace · 03/19 10:52
Briacell Therapeutics Corp reports results for the quarter ended in January - Earnings Summary
Briacell Therapeutics Corp reports results for the quarter ended in January. The company reported a quarterly adjusted loss of 71 cents per share. The lone analyst forecast was for a loss of 20 cents. Briacell's shares had fallen by 49.6% this quarter.
Reuters · 03/18 22:43
Weekly Report: what happened at BCTX last week (0311-0315)?
Weekly Report · 03/18 11:16
Weekly Report: what happened at BCTX last week (0304-0308)?
Weekly Report · 03/11 11:12
Briacell Therapeutics Corp <BCT.TO> expected to post a loss of 20 cents a share - Earnings Preview
Briacell Therapeutics Corp BCT.TO expected to post a loss of 20 cents a share. The one available analyst rating on the shares is "buy" Wall Street's median 12-month price target for the company is $18.00. The company is expected to report results on March 11.
Reuters · 03/08 21:27
BriaCell Partners to Propel Cancer Vaccine Development
BriaCell Therapeutics has entered a significant agreement with the University of Texas MD Anderson Cancer Center to develop cancer vaccines. The company is developing immunotherapies for breast and prostate cancer. BriaCell has a market capitalization of TSE:BCT.
TipRanks · 03/07 13:37
BriaCell Receives And Executes Letter Of Intent To Advance Clinical Development Of Breast And Prostate Cancer Immunotherapies
Agreement with a leading cancer treatment group to advance the clinical development of BriaCell's novel off-the-shelf personalized cancer vaccines, marks a major milestone for the company. University of Texas MD Anderson Cancer Center to develop Bria-OTS+ in advanced breast cancer and prostate cancer.
Benzinga · 03/07 13:02
BriaCell Showcases Cancer Breakthroughs at AACR
TipRanks · 03/06 13:37
More
Webull provides a variety of real-time BCTX stock news. You can receive the latest news about Briacell Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.